Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 2/20 | 0.34 |
| ▸ | FNTB | P49356 | 2/20 | 0.34 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999224 | 0.88 | NPSR1 (0.34) | PDCD1CD274 | |
| SCHEMBL1995752 | 0.87 | PDCD1 (0.40) | PTGDR2CNR2SLC22A12HPGDSCHRM3 | |
| SCHEMBL12569158 | 0.85 | PTGDR2 (0.39) | PTGDR2SLC22A12HPGDSFNTAFNTB | |
| SCHEMBL1999450 | 0.73 | ALDH1A1 (0.39) | ADAMTS4PDCD1CD274 | |
| SCHEMBL12569156 | 0.72 | PDCD1 (0.42) | PTGDR2SLC22A12FNTAFNTBADAMTS4 | |
| SCHEMBL12569145 | 0.70 | ALDH1A1 (0.38) | ADAMTS4PDCD1CD274 | |
| SCHEMBL1997049 | 0.68 | ITGB2 (0.34) | — | |
| SCHEMBL1993187 | 0.68 | MTNR1A (0.34) | — | |
| SCHEMBL15564582 | 0.64 | PPARA (0.56) | — | |
| SCHEMBL396202 | 0.62 | ADRA2C (0.59) | ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960373-B2 | 2-alkoxy-3,4,5-trihydroxyalkylamide-benzothiazepines preparation thereof, compositions containing them and use thereof | SANOFI-AVENTIS (FR) | 2011-06-14 | — | — | US | disclosed |
| EP-2029596-B1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZOTHIAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI AVENTIS (FR) | 2010-02-24 | — | — | EP | disclosed |
| US-20090093459-A1 | 2-ALKOXY-3,4,5-TRIHYDROXYALKYLAMIDE-BENZOTHIAZEPINES PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093459-A1 | 2-ALKOXY-3,4,5-TRIHYDROXYALKYLAMIDE-BENZOTHIAZEPINES PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | TPH2, CYP4B1, HTR3C | PTGDR2 285/4885CNR2 38/4885SLC22A12 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.